Cecilia Zhang
Company: Biosyngen Group
Job title: Chief Scientific Officer
Seminars:
Roundtable Discussion: Highlighting Key TIL Genetic Targets Amenable for Engineering Enhanced TILs 12:00 pm
Discussing which TIL genes may be of interest to amend for desired characteristics What makes a TIL gene a good target for modification? What are some of the most common TIL genes being modified and what makes them good targets?Read more
day: Conference Day One - Track A - AM
Cutting-Edge MSETM-TIL Platform for Enhanced Anti- Tumor Efficacy with Broader Clinical Applications 1:30 pm
Introduction of the company and the backgroundUnique features of Biosyngen’s MSETM-TIL platform Efficient ex vivo expansion from tumor biopsy samples Efficient genetic modification system Pre-clinical data on anti-tumor efficacy of the MSETM-TIL systemRead more
day: Conference Day One - Track B - PM
Preclinical & Translation 10:15 am
day: Conference Day One - Track A - AM
Preclinical & Translation 10:30 am
day: Conference Day Two - Track A - AM